These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9265913)

  • 21. [Psychopathology of schizophrenia and brain imaging].
    Gross G; Huber G
    Fortschr Neurol Psychiatr; 2008 May; 76 Suppl 1():S49-56. PubMed ID: 18461545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and molecular neuropathology of schizophrenia: new directions from developmental neurobiology.
    Turner EE; Fedtsova N; Jeste DV
    Schizophr Res; 1997 Oct; 27(2-3):169-80. PubMed ID: 9416646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
    Jann MW
    Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future.
    Alaerts M; Del-Favero J
    Hum Mutat; 2009 Aug; 30(8):1139-52. PubMed ID: 19626716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.
    Winterer G
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S68-71. PubMed ID: 16508900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neurobiological findings in schizophrenia].
    Lingjaerde O
    Tidsskr Nor Laegeforen; 2002 Sep; 122(21):2123-7. PubMed ID: 12555651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating genetic, functional genomic, and bioinformatics data in a systems biology approach to complex diseases: application to schizophrenia.
    Middleton FA; Rosenow C; Vailaya A; Kuchinsky A; Pato MT; Pato CN
    Methods Mol Biol; 2007; 401():337-64. PubMed ID: 18368374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia susceptibility genes: emergence of positional candidates and future directions.
    Gogos JA; Gerber DJ
    Trends Pharmacol Sci; 2006 Apr; 27(4):226-33. PubMed ID: 16530856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurodevelopmental animal models of schizophrenia.
    Lillrank SM; Lipska BK; Weinberger DR
    Clin Neurosci; 1995; 3(2):98-104. PubMed ID: 7583625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Meyer U; Feldon J
    Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmortem neurochemistry in schizophrenia.
    Bracha HS; Kleinman JE
    Psychiatr Clin North Am; 1986 Mar; 9(1):133-41. PubMed ID: 2421270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gaba blockade, dopamine and schizophrenia: experimental activation of the mesolimbic system.
    Stevens JR
    Int J Neurol; 1975; 10(1-4):115-27. PubMed ID: 1237474
    [No Abstract]   [Full Text] [Related]  

  • 35. Schizophrenia: diverse approaches to a complex disease.
    Sawa A; Snyder SH
    Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation.
    Fitsanakis VA; Au C; Erikson KM; Aschner M
    Neurochem Int; 2006; 48(6-7):426-33. PubMed ID: 16513220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia.
    Williams M
    Curr Opin Investig Drugs; 2003 Jan; 4(1):31-6. PubMed ID: 12625025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in schizophrenia.
    Thaker GK; Carpenter WT
    Nat Med; 2001 Jun; 7(6):667-71. PubMed ID: 11385502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Do the glutamate excitotoxicity theory and potential free radicals implication in schizophrenia aetiopathogenesis provide a new enlightenment to links between: genome, environment and biology in the determinism of that disorder?].
    Nguimfack Mbodie PC
    Encephale; 2002; 28(2):147-53. PubMed ID: 11972141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in postmortem pathology and neurochemistry in schizophrenia.
    Dean B; Boer S; Gibbons A; Money T; Scarr E
    Curr Opin Psychiatry; 2009 Mar; 22(2):154-60. PubMed ID: 19553869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.